The commercial pharmacy channel is getting more transparent. CAA-era PBM reform, the FTC’s pursuit of the large PBMs and their group-purchasing affiliates, and the drift toward point-of-sale and pass-through economics all push in the same direction: a lower, more visible net price for the plan sponsor and the patient. Manufacturers and payers have mostly read that as good news. For a specific and fast-growing part of overall US drug spend, it does the opposite. The same forces that thin the commercial spread everywhere else deepen the one discount no one negotiates and few can see, which is that nettlesome and growing behemoth I’ve written about before: 340B.

Here are four consequences that follow from that, and what they mean for a manufacturer trying to protect brand margin without walking into a compliance problem.

1. Transparency Grows the 340B Program

The 340B ceiling price is a formula, not a negotiation. It equals Average Manufacturer Price (AMP) minus the Unit Rebate Amount (URA), and for a single-source brand, the URA is the greater of 23.1% of AMP or AMP minus Best Price, plus the CPI-U inflation penalty. Lower the real commercial net and Best Price falls with it. Once Best Price falls, the gap between AMP and Best Price widens, the URA climbs, and the ceiling drops. The American Rescue Plan removed the cap that once held total rebates at 100% of AMP, effective January 2024, so that ceiling can now fall all the way to a penny (“negative rebates,” anyone…?).

Every win the transparency movement notches on the commercial side therefore flows through Best Price into a deeper acquisition discount for covered entities. Reimbursement on those same claims does not fall nearly as fast because the plan sets it, not the formula. The distance between what a hospital pays and what it collects widens exactly as the rest of the channel tightens.

A second pull reinforces the first. As pass-through PBM models and point-of-sale rebates compete margin out of every other node, 340B stays put. It is a statutory entitlement rather than a discount anyone can renegotiate, which leaves it standing as the last protected margin in the system. Capital follows margin. The contract-pharmacy footprint, child-site registrations, and third-party administrators that harvest 340B claims all have reason to expand, and the savings-share intermediaries documented in recent Wall Street Journal reporting proliferate for the same reason. HRSA data already show program purchases rising more than 22% a year, from $66 billion in 2023 to $81.4 billion in 2024. Commercial transparency does not slow that trend, it feeds it.

For ERISA plans, the exposure is more concentrated because large, self-insured employers carry the commercially-paid specialty claims liability where the 340B spread runs widest. Minnesota’s second 340B Covered Entity Report, published in February 2026—and still the only state dataset of its kind—found commercial payers funded roughly 45% of the $1.34 billion in net 340B revenue that covered entities captured in 2024, about $608 million in a single mid-sized state. Extend that pattern across the country and the commercial share of the 340B spread is a multibillion-dollar transfer that ERISA sponsors finance without a line item for it anywhere on their reports. The impact of the uniqueness of the healthcare marketplace may not translate directly to other states, so the magnitude of the effect in other states isn’t a direct 1:1 relationship.

2. ERISA Premiums Rise as Rebate Volume Erodes

This mechanism “brought to you by” the rebate pool. When a commercial claim is captured as 340B eligible after adjudication, the manufacturer rebate on that claim disappears because manufacturers exclude 340B units from commercial rebate eligibility to avoid paying twice on the same script—admittedly, this is an issue that many manufacturers are working to get a good handle on. The plan already paid full price at the point-of-sale. The rebate it counted on to true up that cost never arrives.

Rebates have long subsidized premiums rather than the prescriptions that generated them, which is part of what the recent CAA/FTC actions aim to address in increasing transparency and addressing patient out-of-pocket cost shares. The dollars return in aggregate and get spread across the employer’s covered population to hold premiums down, which is the rationale behind the longtime complaint that the sickest patients end up subsidizing the system in their utilization of expensive specialty therapeutics via the high(er) rebates on the specialty products used. Strip rebates from a growing share of specialty claims and that subsidy shrinks, leaving group premiums to absorb the difference. The 340B program compounding at over 20% a year keeps enlarging the slice of specialty spend that returns no rebate to the plan that paid for it.

Point-of-sale pricing removes the cushion that used to hide this. Retrospective rebates averaged the loss across the book and smoothed it out. Point-of-sale economics put cost where the claim lands, so the 340B leakage changes from being a diffuse drag on the rebate pool and starts appearing as sharper variance on the plan sponsor’s pharmacy line. Sponsors will see it sooner, and they will not like what they see. That is why employer coalitions have already cited the Minnesota commercial-funding figure in Washington and pressed for claims-level transparency.

3. Best Price Changes Jobs

Best Price was created under OBRA ‘90, effective January 1992, to stop manufacturers from giving commercial buyers a better deal than they gave Medicaid. For decades it did roughly that. Uncapping the URA changed its function. With no ceiling on the rebate, Best Price now governs how deep the 340B discount can run, and nothing stops it short of the penny.

Because the 340B ceiling keys off Best Price, any real cut to a manufacturer’s commercial net price via a pass-through PBM deal, a cash-pay benchmark, or MFN pricing pushes Best Price down and deepens the 340B discount by the same amount. The commercial team’s pricing decision and the government-pricing team’s 340B exposure have become the same decision, whether or not the two teams ever speak.

It also raises the stakes on getting Best Price right. The channel feeding the calculation is more tangled than it has ever been. Point-of-sale rebates, copay accumulators, cash-pay platforms, savings-share arrangements, and MFN references each carry Best Price implications, and several sit in gray areas of the price-reporting rules. A misclassified transaction or a missed best-price trigger no longer moves Medicaid rebates alone. It moves the 340B ceiling, and it moves it without a cap. Restatements in that environment carry real False Claims Act exposure, not a simple rounding adjustment.

4. Manufacturers Need Claim-Level Command of Their Own Discounts

A manufacturer that cannot see its claims cannot tell a safety-net script from a financialized one. Both arrive as a 340B chargeback. One reflects the program’s stated purpose, while the other is a contract pharmacy and a TPA splitting a spread on a commercially insured patient who already paid full coinsurance months earlier. The distinction is invisible at the summary level and decisive for margin determination.

The discount waterfall is what makes this urgent. A single specialty unit can carry a statutory 340B ceiling discount, a Medicaid URA, an inflation penalty, a negotiated commercial rebate, GPO administrative fees, and, for selected products, an IRA maximum fair price. Several of these can land on the same claim. Duplicate discounts, 340B stacked on a Medicaid rebate today, and 340B stacked on an IRA maximum fair price tomorrow erode margin twice and create direct compliance liability. Without claim-level identification, a manufacturer cannot prevent the duplication, cannot defend its Best Price and AMP calculations, and cannot state true net by channel with any degree of confidence.

This is the logic behind the manufacturer 340B rebate models and claims-data submission requirements that several large manufacturers have pushed over HRSA’s objection. The control point in a net-priced, transparent channel is the claim. A manufacturer that owns claims-level data can model the interaction of maximum fair price, Medicaid, and 340B before it sets a commercial price, catch duplicate discounts before they post, and defend a Best Price restatement with evidence rather than assertion. A manufacturer that cannot see claims-level data is managing brand margin by inference while discounts stack atop each other in the dark.

The Strategic Read

Commercial transparency and net pricing trends are real and close to irreversible, and for most of the channel, they do what their advocates intend. For 340B, they do the reverse because the program’s discount is pinned to Best Price and Best Price—the cap on the total Medicaid rebate—is now uncapped. A biopharmaceutical manufacturer should treat its 340B exposure as an output of its commercial pricing decisions, not a separate ledger reviewed once a quarter. It should assume ERISA plan sponsors will become more agitated and animated as point-of-sale economics uncover the leakage on their own reports. And it should build claims-level visibility ahead of the discounts stack filling in, rather than reconstruct it after a restatement. The plan sponsors financing the spread are starting to run this arithmetic themselves. The manufacturers whose margin depends on it should not be the last to do the same.

Sources

Minnesota Department of Health, 340B Covered Entity Report to the Legislature (Feb. 2026, 2024 data).

HRSA Program Purchase Data (2023–2024).

The Wall Street Journal, “Employers Get Big Drug Discounts Through a Program for Poor Hospital Patients” (March 2025).

American Rescue Plan Act of 2021 (URA cap removal, eff. Jan. 2024).

Social Security Act §1927 (Medicaid Drug Rebate Program/Best Price).

Figures are drawn from these public sources; strategic interpretations are the author’s.

To learn more, contact advisory@integrichain.com.